In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease
Session

Event : ESC Congress 2019

Topic : Cardiovascular Disease in Special Populations

  • Session type : Satellite Symposium
  • Date : 01 September 2019
  • Time : 15:00 - 16:00
  • Sponsored by Novo Nordisk A/S

5 presentations in this session

Chair’s Welcome

Event : ESC Congress 2019

  • Session : Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease
  • Speaker : L Ryden (Stockholm,SE)
  • Sponsored by Novo Nordisk A/S

Examining the link: type 2 diabetes and cardiovascular disease

Event : ESC Congress 2019

  • Session : Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease
  • Speaker : L Ryden (Stockholm,SE)
  • Sponsored by Novo Nordisk A/S

Gazing into the future opportunities of glucagon-like peptide-1 receptor agonists in cardiovascular disease

Event : ESC Congress 2019

  • Session : Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease
  • Speaker : S Verma (Toronto,CA)
  • Sponsored by Novo Nordisk A/S

“Belling the Cat” - Practical guide for cardiologists on Incorporating GLP-1RAs into comprehensive cardiovascular risk reduction

Event : ESC Congress 2019

  • Session : Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease
  • Speaker : M Kosiborod (Kansas,US)
  • Sponsored by Novo Nordisk A/S

Connecting with the speakers - Questions and answers

Event : ESC Congress 2019

  • Session : Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease
  • Speaker : L Ryden (Stockholm,SE), S Verma (Toronto,CA), M Kosiborod (Kansas,US)
  • Sponsored by Novo Nordisk A/S

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are